Xilio Therapeutics, Inc.XLONASDAQ
Loading
EPS Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+47.8%
5Y CAGR+36.6%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
+47.8%/yr
Quarterly compound
5Y CAGR
+36.6%/yr
Recent acceleration
Percentile
P95
Near historical high
vs 5Y Ago
4.8x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 64.52% |
| Q2 2025 | -72.22% |
| Q1 2025 | 10.00% |
| Q4 2024 | 9.09% |
| Q3 2024 | 31.25% |
| Q2 2024 | 48.39% |
| Q1 2024 | 3.13% |
| Q4 2023 | -4.92% |
| Q3 2023 | 12.86% |
| Q2 2023 | 15.66% |
| Q1 2023 | -1.22% |
| Q4 2022 | -13.89% |
| Q3 2022 | 20.00% |
| Q2 2022 | -15.38% |
| Q1 2022 | 20.41% |
| Q4 2021 | 95.39% |
| Q3 2021 | 32.43% |
| Q2 2021 | -33.79% |
| Q1 2021 | 25.21% |
| Q4 2020 | -30.05% |
| Q3 2020 | 13.55% |
| Q2 2020 | -41.10% |
| Q1 2020 | 0.00% |